Dashboard
1
With a growth in Net Profit of 114.33%, the company declared Very Positive results in Sep 25
- OPERATING CASH FLOW(Y) Highest at CNY 348.33 MM
- RAW MATERIAL COST(Y) Fallen by -6.97% (YoY)
- CASH AND EQV(HY) Highest at CNY 2,210.32 MM
2
With ROE of 9.39%, it has a fair valuation with a 3.35 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,994 Million (Small Cap)
36.00
NA
1.42%
-0.53
11.58%
2.33
Revenue and Profits:
Net Sales:
516 Million
(Quarterly Results - Mar 2026)
Net Profit:
106 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.48%
0%
2.48%
6 Months
6.82%
0%
6.82%
1 Year
24.96%
0%
24.96%
2 Years
47.81%
0%
47.81%
3 Years
-4.74%
0%
-4.74%
4 Years
63.77%
0%
63.77%
5 Years
-12.17%
0%
-12.17%
Edan Instruments, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.99%
EBIT Growth (5y)
-21.82%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.54
Sales to Capital Employed (avg)
0.92
Tax Ratio
1.18%
Dividend Payout Ratio
74.01%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
28.92%
ROE (avg)
15.92%
Valuation key factors
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
3.35
EV to EBIT
41.45
EV to EBITDA
29.72
EV to Capital Employed
5.92
EV to Sales
3.20
PEG Ratio
1.17
Dividend Yield
1.04%
ROCE (Latest)
14.29%
ROE (Latest)
9.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
516.30
552.80
-6.60%
Operating Profit (PBDIT) excl Other Income
113.30
56.20
101.60%
Interest
0.30
0.80
-62.50%
Exceptional Items
0.00
-0.30
100.00%
Consolidate Net Profit
106.20
49.40
114.98%
Operating Profit Margin (Excl OI)
219.40%
73.90%
14.55%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -6.60% vs 3.85% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 114.98% vs -52.18% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,982.70
1,818.40
9.04%
Operating Profit (PBDIT) excl Other Income
352.80
197.20
78.90%
Interest
3.20
2.30
39.13%
Exceptional Items
-1.40
-11.00
87.27%
Consolidate Net Profit
308.00
162.80
89.19%
Operating Profit Margin (Excl OI)
149.20%
77.10%
7.21%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 9.04% vs -5.16% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 89.19% vs -26.53% in Dec 2024
About Edan Instruments, Inc. 
Edan Instruments, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






